Epsicapron en es it fr

Epsicapron Brand names, Epsicapron Analogs

Epsicapron Brand Names Mixture

  • No information avaliable

Epsicapron Chemical_Formula


Epsicapron RX_link


Epsicapron fda sheet

Epsicapron FDA

Epsicapron msds (material safety sheet)

Epsicapron MSDS

Epsicapron Synthesis Reference

No information avaliable

Epsicapron Molecular Weight

131.173 g/mol

Epsicapron Melting Point

205 oC

Epsicapron H2O Solubility

5.05E+005 mg/L

Epsicapron State


Epsicapron LogP


Epsicapron Dosage Forms

Solution for injection (containing 250 mg/mL of aminocaproic acid) and tablets (500, 1000mg)

Epsicapron Indication

For use in the treatment of excessive postoperative bleeding.

Epsicapron Pharmacology

Aminocaproic acid works as an antifibrinolytic. It is a derivative of the amino acid lysine. The fibrinolysis-inhibitory effects of aminocaproic acid appear to be exerted principally via inhibition of plasminogen activators and to a lesser degree through antiplasmin activity.

Epsicapron Absorption

Absorbed rapidly following oral administration. In adults, oral absorption appears to be a zero-order process with an absorption rate of 5.2 g/hr. The mean lag time in absorption is 10 minutes. After a single oral dose of 5 g, absorption was complete (F=1).

Epsicapron side effects and Toxicity

A few cases of acute overdosage with intravenous administration have been reported. The effects have ranged from no reaction to transient hypotension to severe acute renal failure leading to death. The intravenous and oral LD50 were 3.0 and 12.0 g/kg respectively in the mouse and 3.2 and 16.4 g/kg respectively in the rat. An intravenous infusion dose of 2.3 g/kg was lethal in the dog.

Epsicapron Patient Information

Epsicapron Organisms Affected

Humans and other mammals